Ads
related to: worldwide clinical trials- Meet the Team
Discuss Your Clinical Trial
With Our Top Experts.
- About Us
Get In Touch
Let Us Know How We Can Help.
- Request Info or Proposal
Fast & Easy. Submit Your Request
And We'll Be In Touch.
- CRO Quality Ratings
Explore Worldwide Awards,
Accolades & Reviews over 32 years.
- Tour Our New BioA Lab
Large And Small Molecule Processing
Along With Powerful Analysis Tools
- Cell & Gene Therapy
On Time, On Budget Gene Therapy
Clinical Development. Contact Us.
- Meet the Team
cancer.osu.edu has been visited by 10K+ users in the past month
Search results
Institutional Investors are Betting on Roivant Sciences (NASDAQ:ROIV)
Insider Monkey via Yahoo Finance· 4 hours agoWe recently compiled a list of the 7 Best Mid-Cap Healthcare Stocks To Buy Now and in this article...
Ozempic reduces risk of serious illness and death in people with diabetes and kidney disease, study...
CNN via Yahoo News· 4 days agoWeekly injections of semaglutide medications like Ozempic significantly reduce the risk of serious...
Juncell Therapeutics Announces Clinical Data of GC203 TIL therapy in Ovarian Cancer at ASCO 2024
KTLA-TV Los Angeles· 4 days agoShanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech developing innovative Tumor-Infiltrating Lymphocyte (TIL) therapies for cancers, announced ...
NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.
The Kansas City Star· 5 days agoSHELTON, CT / ACCESSWIRE / May 23, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical-stage global leader in broad-spectrum antiviral nanomedicines ...
3 Biotech Stocks That Could Be Millionaire-Makers: May Edition
InvestorPlace· 2 days agoAs we delve deeper into 2024, biotech stocks are commanding the attention of growth-focused...
Study finds feeding infants peanut products protects against allergy into adolescence
Medical Xpress· 13 hours agoFeeding children peanuts regularly from infancy to age five reduced the rate of peanut allergy in...
UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in...
Loudoun Times-Mirror· 5 days agoIn these studies, bimekizumab consistently demonstrated sustained improvements in clinical- as well as patient-reported outcomes for people with moderate to severe disease ...
Medtronic's (MDT) OmniaSecure Lead Favored in the LEADR Trial
Zacks via Yahoo Finance· 4 days agoPresently, it is investigational worldwide and not yet approved for sale or distribution. More on...
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing ...
KSAN - KLST San Angelo· 3 days agoNovartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G study of Fabhalta® (iptacopan) at the late-breaking clinical trials session ...
Further CYP-001 GvHD Clinical Data Published in Nature Medicine
WKRN Nashville· 5 days agoCynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the ...
Ads
related to: worldwide clinical trialscancer.osu.edu has been visited by 10K+ users in the past month